bluebird bio (BLUE) Given “Hold” Rating at Maxim Group

Maxim Group reissued their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research report released on Monday morning.

Several other research firms have also recently commented on BLUE. BidaskClub cut shares of bluebird bio from a sell rating to a strong sell rating in a research report on Tuesday, October 23rd. Oppenheimer restated a hold rating on shares of bluebird bio in a research report on Tuesday, November 27th. Goldman Sachs Group cut shares of bluebird bio from a conviction-buy rating to a buy rating in a research report on Friday, September 21st. Morgan Stanley decreased their target price on shares of bluebird bio from $190.00 to $186.00 and set an equal weight rating for the company in a research report on Monday, October 15th. Finally, Guggenheim started coverage on shares of bluebird bio in a research report on Monday, September 17th. They issued a neutral rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eighteen have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $200.80.

Shares of NASDAQ:BLUE opened at $116.50 on Monday. bluebird bio has a fifty-two week low of $102.21 and a fifty-two week high of $236.17. The stock has a market cap of $6.72 billion, a P/E ratio of -15.11 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the consensus estimate of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The firm had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the prior year, the firm earned ($1.73) EPS. bluebird bio’s quarterly revenue was up 49.2% on a year-over-year basis. On average, research analysts expect that bluebird bio will post -10.57 earnings per share for the current year.

In other news, insider Jeffrey T. Walsh sold 1,500 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the transaction, the insider now directly owns 36,995 shares in the company, valued at $5,555,169.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Davidson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total transaction of $696,600.00. Following the completion of the transaction, the insider now owns 29,905 shares of the company’s stock, valued at $4,166,364.60. The disclosure for this sale can be found here. Insiders sold 17,600 shares of company stock valued at $2,443,947 over the last quarter. Insiders own 3.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of BLUE. Stratos Wealth Partners LTD. acquired a new stake in bluebird bio during the third quarter valued at approximately $106,000. Belpointe Asset Management LLC acquired a new stake in bluebird bio during the third quarter valued at approximately $110,000. NuWave Investment Management LLC lifted its stake in bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in bluebird bio during the second quarter valued at approximately $201,000.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: What are the benefits of a balanced fund?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit